[{"data":1,"prerenderedAt":244},["ShallowReactive",2],{"$f1tmgmvqil1qta":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":55,"top_diseases":82,"top_companies":114,"key_results":139,"trends":231,"previous_editions":240,"comparison":144,"highlighted_classes":241},1,"easl-2026","EASL","easl","EASL Congress 2026",2026,"Gastroenterology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},2271,718,191,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},30,8,49,2,5,38,[24,28,31,34,38,40,42,45,49,52],{"name":25,"count":26,"share":27},"NTCP",46,6,{"name":29,"count":30,"share":27},"CD274",45,{"name":32,"count":33,"share":21},"ABCC2",35,{"name":35,"count":36,"share":37},"GLP1R",32,4,{"name":39,"count":36,"share":37},"THRB",{"name":41,"count":17,"share":37},"PPARD",{"name":43,"count":44,"share":37},"PPARA",29,{"name":46,"count":47,"share":48},"HBsAg",22,3,{"name":50,"count":51,"share":48},"HBV Pol",20,{"name":53,"count":54,"share":20},"FGFR1",12,[56,60,64,67,71,73,76,79],{"name":57,"count":58,"share":59},"Small molecules",452,63,{"name":61,"count":62,"share":63},"Monoclonal antibodies",92,13,{"name":65,"count":66,"share":54},"Peptides",88,{"name":68,"count":69,"share":70},"Non-antibody therapeutic proteins",72,10,{"name":72,"count":30,"share":27},"Oligonucleotide and RNA therapeutics",{"name":74,"count":75,"share":37},"Carbohydrate, lipid and polymer therapeutics",31,{"name":77,"count":78,"share":48},"Blood, tissue and cell-derived products",25,{"name":80,"count":81,"share":20},"Vaccines",14,[83,87,91,94,97,99,102,105,108,111],{"name":84,"count":85,"share":86},"Cirrhosis",129,18,{"name":88,"count":89,"share":90},"hepatocellular carcinoma (HCC)",118,16,{"name":92,"count":93,"share":81},"metabolic dysfunction-associated steatohepatitis (MASH)",104,{"name":95,"count":96,"share":81},"hepatitis B (HBV)",97,{"name":98,"count":62,"share":63},"metabolic dysfunction-associated steatotic liver disease (MASLD)",{"name":100,"count":101,"share":54},"hepatic fibrosis",83,{"name":103,"count":104,"share":70},"primary biliary cholangitis (PBC)",73,{"name":106,"count":107,"share":18},"hepatitis D (HDV)",54,{"name":109,"count":110,"share":37},"Portal Hypertension (PH)",28,{"name":112,"count":113,"share":37},"Chronic Hepatitis B (CHB)",27,[115,118,121,123,126,128,130,132,135,137],{"name":116,"count":117,"share":70},"Gilead Sciences",74,{"name":119,"count":120,"share":27},"Genentech",43,{"name":122,"count":75,"share":37},"TPG Capital",{"name":124,"count":125,"share":37},"Madrigal Pharmaceuticals",26,{"name":127,"count":78,"share":48},"GSK",{"name":129,"count":86,"share":48},"Ipsen",{"name":131,"count":90,"share":20},"Roche",{"name":133,"count":134,"share":20},"Novo Nordisk",15,{"name":136,"count":81,"share":20},"Bristol Myers Squibb",{"name":138,"count":81,"share":20},"Merck",[140,150,156,163,172,179,189,197,204,212,219,225],{"title":141,"drug":142,"company":145,"phase":146,"disease":147,"finding":148,"url":149},"Plasma exchange with albumin 5% significantly increases 90-day overall survival in acute-on-chronic liver failure: topline results of the APACHE trial",{"name":143,"slug":144},"albumin (human)",null,"Grifols","Phase 3","acute-on-chronic liver failure (ACLF)","SMT+PE-A5% significantly increased 90-day OS compared to SMT (Hazard Ratio [HR] [95% CI] = 0.65 [0.45, 0.94]; p = 0.021).","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYPkBEjqLItT5HIvj8owVTuHJ6iJJcowQvDi-2McOBWxs0",{"title":151,"drug":152,"company":144,"phase":146,"disease":106,"finding":154,"url":155},"Lonafarnib\u002Fritonavir with or without peginterferon achieves rapid, durable responses in a chronic hepatitis D: extended analyses from the phase 3 D-LIVR trial",{"name":153,"slug":153},"lonafarnib","LNF\u002FRTV+Peg patients demonstrated ≥ 2 log HDV RNA reduction at a median time of 8.3 weeks (95% CI: 8.1-12.1) compared to 28.3 weeks (95% CI: 16.3-48.1) for Peg monotherapy using Kaplan Meier estimates.","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYPEIeGmOsWIcU8JWrmWNNXrtI1T0pJLtkoGZPlz2YGI30",{"title":157,"drug":158,"company":144,"phase":160,"disease":103,"finding":161,"url":162},"A phase 2b\u002F3 trial of saroglitazar in primary biliary cholangitis (EPICS III)",{"name":159,"slug":159},"saroglitazar","Phase 2\u002F3","Biochemical response was achieved in 56.7% with saroglitazar compared to 9.8% with placebo (difference, 48.0%; 95% CI, 35.3 to 60.8; p \u003C 0.001).","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYP8Q0tsED4q0ybpDH1qyJEz-S5bp1dEw9uNlSdAzldAm0",{"title":164,"drug":165,"company":168,"phase":169,"disease":92,"finding":170,"url":171},"HSK31679, a thyroid hormone receptor beta agonist, improves histological outcomes in Asian patients with MASH and F2–F3 fibrosis: a 52-week phase 2b randomized, double-blind, placebo-controlled trial",{"name":166,"slug":167},"HSK31679","hsk31679","Haisco Pharmaceutical Group","Phase 2","More participants receiving HSK31679 achieved ≥ 30% reduction in MRI-PDFF at week 52 (52.5% and 53.3% vs 25.0%; both p \u003C 0.01).","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYImKGEJ5FdueWFFe17Um53rV3RPYiskxfoowXHbZ58e10",{"title":173,"drug":174,"company":176,"phase":169,"disease":92,"finding":177,"url":178},"Week 48 top-line results from the phase 2b, multicenter, randomized, placebo-controlled IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis",{"name":175,"slug":175},"pemvidutide","Altimmune","A greater proportion of patients treated with pemvidutide achieved a ≥ 30% reduction in LSM than placebo [1.2 mg (61.1%; p \u003C 0.0001), 1.8 mg (63.9%; p \u003C 0.0001), placebo (21.2%)].","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYAyoVRW3ErAQ0H3lBlKxt0pnM6pu1Qi-C1F95QixvCB60",{"title":180,"drug":181,"company":185,"phase":169,"disease":186,"finding":187,"url":188},"Efficacy and safety of CAM2029 in patients with polycystic liver disease: phase 2b POSITANO study",{"name":182,"slug":183,"named_as":184},"octreotide hydrochloride","octreotide-hydrochloride","CAM2029","Camurus","Polycystic liver disease (PLD)","The most frequent AEs with CAM2029 were diarrhoea (68.1%), injection site pruritus (42.6%), injection site pain (40.4%) and abdominal pain (36.2%).","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYLtdfdrBXHEm5J5409xkI7JNjouB7piItOCFJ_PH_TtA0",{"title":190,"drug":191,"company":194,"phase":169,"disease":92,"finding":195,"url":196},"Weight loss–independent Glucagon effect led to rapid, clinically significant reductions in MASH severity, including steatosis and liver stiffness, during a 48-week randomized controlled trial of dual agonist DD01",{"name":192,"slug":193},"DD-01","dd-01","D&D Pharmatech","Among patients with \u003C5% bodyweight loss, those treated with DD01 achieved a 37.4% reduction in MRI-PDFF (95% CI, -72.9, -1.9), versus an increase of 1.6% (-30.4, 33.6) in placebo subjects.","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYNbEtFGihbqK6m3jucZMBb3VwoalLY3RtSfN2P9ZN8RM0",{"title":198,"drug":199,"company":201,"phase":169,"disease":103,"finding":202,"url":203},"Linafexor in UDCA-inadequate PBC: A phase 2 trial of a pulsatile FXR agonist",{"name":200,"slug":200},"linafexor","Cascade Pharmaceuticals","Cumulative composite response rates reached 39.6% (original linafexor) and 30.8% (crossover).","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYIDtfTNnAOaxBgCr4iqircrkxIUMAQLd9pY0bZdqiwke0",{"title":205,"drug":206,"company":209,"phase":169,"disease":92,"finding":210,"url":211},"Norucholic acid reduces histological and biochemical inflammation in metabolic dysfunction-associated steatohepatitis: results from the phase 2b randomized clinical trial NUT-3",{"name":207,"slug":208},"norursodeoxycholic acid","norursodeoxycholic-acid","Dr. Falk Pharma","Resolution of MASH with no worsening of fibrosis was observed in 27.7% of 1,500 mg NCA patients vs. 19.0% of placebo patients (p=0.18), while improvement of fibrosis with no worsening of MASH was reported for 18.1% of 1,500 mg NCA patients vs. 20.6% of placebo patients.","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYAHVJn9dohXCgQJlwh4U_AaVKeoxZUbzE0UPksbx4zu20",{"title":213,"drug":214,"company":216,"phase":169,"disease":106,"finding":217,"url":218},"SOLSTICE week 48 subgroup analysis: Impact of BMI on ALT normalization after successful viral control in participants with chronic hepatitis delta virus infection treated with tobevibart plus elebsiran",{"name":215,"slug":215},"tobevibart","Vir Biotechnology","After 48 weeks, HDV RNA decreased by ≥2 log10 from baseline in 97% (31\u002F32) of participants receiving tobevibart+elebsiran Q4W and HDV RNA target not detected (TND) was achieved by 66% (21\u002F32) of participants.","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYEhGyE_GcvLu1C6bXnKmUd82LM_pekNbkoz9_rcekMu40",{"title":220,"drug":221,"company":127,"phase":169,"disease":92,"finding":223,"url":224},"Once-monthly efimosfermin alfa in participants with metabolic dysfunction-associated steatohepatitis with F2\u002FF3 fibrosis: post hoc results from a 24-week, randomized, double-blind, placebo-controlled, phase 2 trial",{"name":222,"slug":222},"efimosfermin","A greater proportion of pts in the efimosfermin 225 mg and 300 mg groups achieved a response (8% [1\u002F12] and 7% [5\u002F68], respectively) compared with placebo (3%; 1\u002F40).","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYMceZPSPgkj3QVSUchH5pXa3BDroyOxJvy8RN6gAMQ-Q0",{"title":226,"drug":227,"company":144,"phase":169,"disease":92,"finding":229,"url":230},"The combination of senolytic drugs, dasatinib plus quercetin, reduces liver fibrosis in metabolic dysfunction–associated steatohepatitis: a phase 2 randomized double‐blind placebo controlled study: The TRUTH study",{"name":228,"slug":228},"dasatinib","In the D+Q group, 14\u002F17 participants reported adverse events (AE) compared to 6 with placebo.","https:\u002F\u002Fevents-distribution.easl.eu\u002Ffrom.storage?image=X9WvFraREucXDOc3lNmAYM63tecmRFPb1C2xYNEA6Ab0yYL95J8CeIjG_KVZbhj50",{"summary":232,"bullets":234},[233],"Small molecules were the most frequent modality (63% of drug-linked abstracts). NTCP was the most frequent target (6%). Cirrhosis was the most frequent disease (18%).",[235,236,237,238,239],"Gilead Sciences had the largest company share (10% of drug-linked abstracts).","GLP-1 receptor drugs accounted for 4% of drug-linked abstracts.","Monoclonal antibodies were the next most frequent modality (13%).","CD274 was the next most frequent target (6%).","Hepatocellular carcinoma (HCC) was the next most frequent disease (16%).",[],[242],{"name":243,"count":36,"share":37,"previous_count":144,"previous_share":144,"direction":144},"GLP-1 receptor drugs",1793970603081]